Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce Strober

Showing results (101-110 of 130) with videos related to

Pageof 13
Sort By:
Immunotherapy|May 8, 2023
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summaryBruce Strober, Diamant Thaçi, Howard Sofen, et al.
Dermatology and Therapy|December 12, 2025
Summary of Research: Apremilast in Japanese Patients with Palmoplantar Pustulosis: A Randomized, Phase 3 TrialTadashi Terui, Yukari Okubo, Satomi Kobayashi, et al.
Lancet (London, England)|September 22, 2023
Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trialAkimichi Morita, Bruce Strober, A David Burden, et al.
Dermatology and Therapy|December 14, 2021
Unmet Educational Needs and Clinical Practice Gaps in the Management of Generalized Pustular Psoriasis: Global Perspectives from the Front LineBruce Strober, Joyce Leman, Maja Mockenhaupt, et al.
Journal of the American Academy of Dermatology|September 17, 2022
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trialBruce Strober, Diamant Thaçi, Howard Sofen, et al.
Journal of the American Academy of Dermatology|November 28, 2016
Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated dataBruce Strober, Craig Leonardi, Kim A Papp, et al.
Journal of the American Academy of Dermatology|May 22, 2016
Clinical meaningfulness of complete skin clearance in psoriasisBruce Strober, Kim A Papp, Mark Lebwohl, et al.
The Journal of Allergy and Clinical Immunology|December 29, 2023
Efficacy and safety of rademikibart (CBP-201), a next-generation mAb targeting IL-4Rα, in adults with moderate to severe atopic dermatitis: A phase 2 randomized trial (CBP-201-WW001)Jonathan I Silverberg, Bruce Strober, Brian Feinstein, et al.
Journal of the American Academy of Dermatology|July 12, 2022
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trialApril W Armstrong, Melinda Gooderham, Richard B Warren, et al.
The Journal of Dermatological Treatment|June 30, 2024
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trialsNeil J Korman, Richard B Warren, Jerry Bagel, et al.
Pageof 13

Showing results (101-110 of 130) with videos related to

Sort By:
Pageof 13
Immunotherapy|May 8, 2023
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summaryBruce Strober, Diamant Thaçi, Howard Sofen, et al.
Dermatology and Therapy|December 12, 2025
Summary of Research: Apremilast in Japanese Patients with Palmoplantar Pustulosis: A Randomized, Phase 3 TrialTadashi Terui, Yukari Okubo, Satomi Kobayashi, et al.
Lancet (London, England)|September 22, 2023
Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trialAkimichi Morita, Bruce Strober, A David Burden, et al.
Dermatology and Therapy|December 14, 2021
Unmet Educational Needs and Clinical Practice Gaps in the Management of Generalized Pustular Psoriasis: Global Perspectives from the Front LineBruce Strober, Joyce Leman, Maja Mockenhaupt, et al.
Journal of the American Academy of Dermatology|September 17, 2022
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trialBruce Strober, Diamant Thaçi, Howard Sofen, et al.
Journal of the American Academy of Dermatology|November 28, 2016
Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated dataBruce Strober, Craig Leonardi, Kim A Papp, et al.
Journal of the American Academy of Dermatology|May 22, 2016
Clinical meaningfulness of complete skin clearance in psoriasisBruce Strober, Kim A Papp, Mark Lebwohl, et al.
The Journal of Allergy and Clinical Immunology|December 29, 2023
Efficacy and safety of rademikibart (CBP-201), a next-generation mAb targeting IL-4Rα, in adults with moderate to severe atopic dermatitis: A phase 2 randomized trial (CBP-201-WW001)Jonathan I Silverberg, Bruce Strober, Brian Feinstein, et al.
Journal of the American Academy of Dermatology|July 12, 2022
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trialApril W Armstrong, Melinda Gooderham, Richard B Warren, et al.
The Journal of Dermatological Treatment|June 30, 2024
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trialsNeil J Korman, Richard B Warren, Jerry Bagel, et al.
Pageof 13